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Abstract 
Infectious bronchitis virus (IBV) causes a major disease problem for the poultry industry worldwide. The currently used 
live‑attenuated vaccines have the tendency to mutate and/or recombine with circulating field strains resulting in the 
emergence of vaccine‑derived variant viruses. In order to circumvent these issues, and to develop a vaccine that is 
more relevant to Egypt and its neighboring countries, a recombinant avirulent Newcastle disease virus (rNDV) strain 
LaSota was constructed to express the codon‑optimized S glycoprotein of the Egyptian IBV variant strain IBV/Ck/EG/
CU/4/2014 belonging to GI‑23 lineage, that is prevalent in Egypt and in the Middle East. A wild type and two modified 
versions of the IBV S protein were expressed individually by rNDV. A high level of S protein expression was detected 
in vitro by Western blot and immunofluorescence analyses. All rNDV‑vectored IBV vaccine candidates were genetically 
stable, slightly attenuated and showed growth patterns comparable to that of parental rLaSota virus. Single‑dose vac‑
cination of 1‑day‑old SPF White Leghorn chicks with the rNDVs expressing IBV S protein provided significant protec‑
tion against clinical disease after IBV challenge but did not show reduction in tracheal viral shedding. Single‑dose vac‑
cination also provided complete protection against virulent NDV challenge. However, prime‑boost vaccination using 
rNDV expressing the wild type IBV S protein provided better protection, after IBV challenge, against clinical signs and 
significantly reduced tracheal viral shedding. These results indicate that the NDV‑vectored IBV vaccines are promising 
bivalent vaccine candidates to control both infectious bronchitis and Newcastle disease in Egypt.
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(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Infectious bronchitis (IB) is an acute, highly contagious 
viral disease of chickens. IB affects chickens of all ages 
and based on the organ system affected the disease is 
manifested in three major clinical forms—respiratory, 
renal and reproductive. IB causes great economic losses 
in the poultry industry worldwide [1, 2]. Infectious bron-
chitis virus (IBV) is a member of the genus Gammacoro-
navirus in the family Coronaviridae. The viral genome is 
a single-stranded, positive-sense RNA of about 27.6  Kb 
in length [3]. The 5′-two-third of the viral genome codes 
for the non-structural proteins responsible for RNA rep-
lication and transcription. The 3′-one-third of the viral 
genome codes for four structural proteins, namely, spike 
(S), envelope (E), membrane (M) and nucleocapsid (N) 
proteins, in addition to several non-structural proteins 
[3].
The S protein of IBV is heavily glycosylated and plays 
a major role in eliciting protective immune responses. 
It is present as trimers on the surface of the virion and 
contains conformation dependent epitopes [4]. The 
S protein is cleaved post-translationally by host cell 
proteases into S1 (N-terminal, globular head domain) 
and S2 (C-terminal, stalk domain) subunits [5–7]. The 
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S1 subunit is the most variable subunit that harbors 
the major neutralizing epitopes [8, 9] and the recep-
tor binding domain (RBD) responsible for viral attach-
ment and tissue tropism [5]. The S2 subunit is the most 
conserved subunit and is involved in mediating mem-
brane fusion and viral entry [5]. The S2 protein also 
contains minor neutralizing epitopes and contributes 
to the avidity of S1 protein [10]. It has been shown that 
a tyrosine motif located in the cytoplasmic tail of the 
S protein is responsible for the intracellular retention 
[11]. This tyrosine residue is essential for productive 
virus infection [12]. However, the role of this tyrosine 
residue on induction of protective immune response by 
IBV S protein has not been studied.
Many different IBV serotypes and genotypes circulate 
worldwide [2, 6, 13]. These serotypes arise due to high 
frequency of mutations and/or recombination events [14, 
15]. Cross-protection between different serotypes is vari-
able or poor [16].
In Egypt, classical and variant strains of IBV co-cir-
culate causing frequent disease outbreaks [17, 18]. The 
majority of IBV variant strains reported in Egypt belong 
to GI-23 lineage [19]. The Egyptian variant strains are 
mostly related to strains IS/885/00 and IS/1494/06, 
also known as Israeli Variant II [17, 18]. Israeli Variant 
II-related serotypes have also been reported in many 
countries in the Middle East and North Africa [20] and 
recently, in Poland [21] and Turkey [22].
Live-attenuated vaccines have been highly successful in 
controlling IB in the field [23, 24]. However, live-attenu-
ated vaccines provide cross-protection against some of 
the IBV variants but not all [24–26]. Furthermore, use of 
live-attenuated IBV vaccines can lead to production of 
variant IBV strains by mutations and/or recombination 
[27, 28].
In Egypt, classical and variant live-attenuated vaccine 
strains, mainly H120 and 793B, are used to control IB. 
Although these vaccines provide good protection against 
some of the variant viruses, they provide poor protec-
tion against the prevalent variant field viruses belonging 
to GI-23 lineage. These live-attenuated vaccines are also 
a source for generation of new variant viruses [27, 29, 30]. 
Therefore, an alternative vaccine strategy will be benefi-
cial to control IB outbreaks in Egypt.
Viral vectored vaccines provide an alternative approach 
to live-attenuated IBV vaccines. A vectored vaccine 
expressing the protective antigen of IBV will not lead to 
creation of variant viruses. Attempts have been made 
to express S1 or S2 subunits of S protein using fowl pox 
virus, herpes virus and adenovirus vectors [31–34]. How-
ever, none of these vaccines are effective in providing 
complete protection against IBV, suggesting the need for 
new vaccine vectors.
Use of Newcastle disease virus (NDV) as a vaccine 
vector for IBV holds great promise. NDV is a member 
of the genus Avulavirus in the family Paramyxoviridae 
[35]. NDV causes a highly contagious disease with sub-
stantial mortality in chickens [36]. The natural avirulent 
NDV strain LaSota is widely used as a live NDV vaccine 
in chickens for more than 60 years with a good record of 
safety and stability. NDV replicates efficiently in the res-
piratory tract of chickens inducing mucosal immunity 
at the site of IBV entry and it also elicits strong humoral 
and cell-mediated immune responses crucial for clear-
ance of IBV [37]. Moreover, it can be used as a dual vac-
cine against IBV and NDV.
Recombinant NDV (rNDV) has been used previously 
as a vaccine vector to evaluate the protective efficacy 
of S1, S2 and S proteins of IBV [38–40]. It was reported 
that rNDV expressing the S2 protein provided only par-
tial protection against virulent IBV challenge [39]. rNDV 
expressing the IBV S1 protein provided partial protec-
tion after a single vaccination and better protection was 
observed after a booster vaccination [38]. Recently, it was 
shown that the rNDV expressing the whole S protein of 
classical IBV M41 strain provided better protection than 
the rNDVs expressing S1 or S2 protein of IBV [40].
The goal of this study was to evaluate the protec-
tive efficacies of three forms of the S protein of Egyp-
tian IBV GI-23 lineage variant strain IBV/Ck/EG/
CU/4/2014 using NDV as a vaccine vector. In addition to 
the expression of wild type S protein, a second S protein 
was expressed in which the tyrosine residue in the cyto-
plasmic tail was mutated to alanine, and the modified S 
protein was fused to the last 12 amino acids of NDF F 
protein. A third S protein was expressed in which only 
the cytoplasmic tail (CT) of S protein was replaced with 
last 12 amino acids of NDV F protein CT. The CT modi-
fication was done to enhance incorporation of IBV S pro-
tein into NDV envelope. The protective efficacies of the 
three IBV S proteins were evaluated by homologous chal-
lenge with the Egyptian strain IBV/Ck/EG/CU/4/2014.
Materials and methods
Cells and viruses
Human epidermoid carcinoma (HEp-2) and chicken 
embryo fibroblast (DF-1) cell lines were cultured in Dul-
becco’s minimal essential medium (DMEM) with 10% 
fetal bovine serum. Specific pathogen free (SPF) embry-
onated chicken eggs (ECE) were obtained from Charles 
River Laboratories, Manassas, VA, USA. The Egyptian 
IBV strain IBV/Ck/EG/CU/4/2014 belonging to GI-23 
lineage (GenBank accession number: KY805846) [27], 
NDV strain LaSota, virulent NDV strain Texas GB (Gen-
Bank accession number: GU978777.1) and modified vac-
cinia strain Ankara expressing T7 polymerase (MVA-T7), 
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a kind gift from Dr Bernard Moss, were used in this 
study. All work related to virulent NDV was performed 
in our USDA certified enhanced animal biosafety level 3 
(ABSL-3+) facility.
Construction of recombinant NDV‑vectored IBV vaccine 
candidates
Three different forms of chicken-codon-optimized S 
gene of the Egyptian IBV strain IBV/Ck/EG/CU/4/2014 
were inserted individually between phosphoprotein (P) 
and matrix (M) protein genes in the LaSota antigenomic 
cDNA backbone using PmeI site [41] to generate three 
different recombinant NDV vectored IBV vaccine candi-
dates (Figure  1). In the first recombinant, rLaSota/wt.S, 
the full chicken-codon-optimized sequence of the IBV S 
gene without any modification was inserted. In the sec-
ond recombinant, rLaSota/S(Y1145A) + Fct12, the tyros-
ine residue present at position 1145 of the IBV S protein 
was mutated to Alanine (Y1145A) by PCR mutagenesis 
and the modified S gene was fused to the last 12 amino 
acids of NDV fusion (F) protein cytoplasmic domain 
using overlap PCR. In the third recombinant, rLaSota/
SΔct + Fct12, the cytoplasmic tail of the IBV S gene was 
replaced by the last 12 amino acids of NDV fusion pro-
tein using fusion PCR technique. All the three forms of 
the IBV S gene were inserted as an independent tran-
scription cassette flanked by the gene-start (GS) and 
gene-end (GE) sequences of the NDV and the “rule of six” 
was ensured in the final length of the recombinant NDV 
genome for efficient replication [42]. Briefly, the codon-
optimized IBV S gene—preceded with GE, intergenic 
sequence (IGS), GS and Kozak sequences, and flanked 
by PmeI sites—was synthesized and cloned in pUC57 
(pUC57-CO.S) by  GenScript® (Additional file  1A). To 
construct rLaSota/wt.S, pUC57-CO.S was digested 
with PmeI (NEB), and the released insert was gel puri-
fied and ligated into full-length rLaSota clone which was 
predigested by PmeI and dephosphorylated by thermo-
stable shrimp alkaline phosphatase (TSAP) (Promega). 
To construct rLaSota/S(Y1145A) + Fct12, primer sets (1 
and 2) and (3 and 4) were used to induce the “Y1145A-
mutation” and add the last 12 aa of NDV F protein using 
pUC57-CO.S as template (Table 1). The two PCR prod-
ucts were then fused using primers (1 and 4) by fusion 
PCR. The fused PCR product was then digested by SmaI 
and StuI (NEB), and ligated into pUC57-CO.S which was 
predigested by SmaI and by StuI, its sequence is natu-
rally present downstream to the S gene, to create pUC57-
CO.S(Y1145A) + Fct12 (Additional file  1B). To construct 
rLaSota/SΔct + Fct12, primer set (1 and 5) was used to 
replace the cytoplasmic tail of IBV S protein by the last 12 
aa of NDV F protein using pUC57-CO.S as template. The 
PCR product was then digested by SmaI and StuI and 
ligated into pUC57-CO.S which is predigested by SmaI 
and StuI to create pUC57-CO.SΔct + Fct12 (Additional 
file 1C). The newly formed pUC57-CO.S(Y1145A) + Fct12 
and pUC57-CO.SΔct + Fct12 were then digested with 
PmeI and the released inserts were ligated individually 
Figure 1 Construction of three recombinant NDVs containing different forms of the S gene of Egyptian IBV variant strain EG/CU/4/2014. 
Schematic representation of different forms of chicken‑codon‑optimized IBV S gene into NDV strain LaSota antigenome cDNA using PmeI site 
between P and M genes to generate IBV vaccine candidates. In each transcriptional cassette, NDV gene‑end (GE), intergenic sequence (IGS), 
gene‑start (GS) and Kozak sequences were added upstream of the IBV S ORF. In rLaSota/wt.S, the full sequence of the IBV S gene without any 
modification (Blue box) was inserted. In rLaSota/S(Y1145A) + Fct12, the tyrosine residue present at position 1145 of the IBV S protein was changed 
into alanine (GCC nt 3453–3455) and the modified S gene was fused to the last 12 amino acids of NDV fusion protein cytoplasmic tail domain (Grey 
box). In rLaSota/SΔct + Fct12, ecto‑ and transmembrane domains of IBV S protein were fused with the last 12 amino acids of NDV fusion protein 
cytoplasmic tail domain.
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into full-length rLaSota clone which was predigested 
by PmeI and dephosphorylated by TSAP to construct 
rLaSota/S(Y1145A) + Fct12 and rLaSota/SΔct + Fct12, 
respectively. The sequences of all inserts were confirmed 
by DNA nucleotide sequencing. The recombinant viruses 
were rescued using the reverse genetic technique as pre-
viously described [43]. Rescued recombinant viruses 
were plaque purified and propagated in 10-day-old SPF 
ECE. The infective allantoic fluids were harvested, ali-
quoted and stored at −70 °C for further work. The inser-
tion of the different forms of IBV S genes were detected 
by RT-PCR using LaSota specific primers flanking the 
PmeI site and confirmed by nucleotide sequencing. 
In vitro characterization of the NDV‑vectored IBV vaccine 
candidates
To compare the multicycle growth kinetics of rLa-
Sota/wt.S, rLaSota/S(Y1145A) + Fct12 and rLaSota/
SΔct + Fct12 with that of parental rLaSota, DF-1 cells 
cultured in six-well plates were infected by the recombi-
nant viruses at MOI of 0.01. After 1  h of virus adsorp-
tion, cells were washed twice with serum-free DMEM 
and then incubated with DMEM containing 2% FBS 
and 10% normal allantoic fluid in 5%  CO2 incubator at 
37  °C. Supernatant media (200  µL) were collected from 
each well at 12 h intervals for 72 h and replaced by equal 
volume of fresh DMEM with 2% FBS and 10% allantoic 
fluid each time. Virus titers of the collected supernatant 
samples were determined by tissue culture infective dose 
50%  (TCID50) titration assay. Briefly, dilutions from  10−1 
to  10−8 of each sample were inoculated on to DF-1 cell 
monolayers in 96-well plates. Four replicate wells were 
used for each dilution. After 1 h of adsorption, cell mon-
olayers were overlaid with DMEM containing 2% FBS 
and 10% normal allantoic fluid and incubated in 5%  CO2 
incubator at 37 °C for 6 days. The  TCID50 was calculated 
according to Reed and Muench method [44]. To check 
the genetic stability, the three recombinant viruses were 
passaged 5 times in ECE and the presence of the different 
forms of the S gene was then checked by RT-PCR using 
 OneTaq® One-Step RT-PCR Kit (New England  Biolabs®, 
Inc) and DNA sequencing using  BigDye® Terminator 
v3.1 cycle sequencing kit (Applied Biosystems, USA) in 
ABI 3130×l genetic analyzer (Applied Biosystems).
Surface and intracellular expression of the different 
forms of the S gene were examined in infected DF-1 cells 
by immunofluorescence and by Western blot analyses. 
Briefly, DF-1 cells grown to 90% confluency on glass slide 
chambers (Nunc Lab-Tek™ II, ThermoFisher, USA) were 
infected with each virus at MOI 0.1. Two chambers were 
used for each virus. At 24  hours post-infection (hpi), 
cells were fixed with 2% paraformaldehyde solution for 
15 min and then quenched by 125 mM glycine for 5 min. 
Cells were then permeabilized with 0.1% Triton X-100 
for 10  min. To demonstrate the surface expression, the 
cell permeabilization step was excluded. Then, cells were 
blocked with 5% goat serum for 30  min and then incu-
bated with chicken polyclonal anti-IBV antibody gener-
ated against the Egyptian strain IBV/Ck/EG/CU/4/2014 
(diluted 1:100) for 2  h, and with goat anti-chicken fluo-
rescein isothiocyanate (FITC) conjugated antibody 
(diluted 1:500) for 45  min. All these steps were carried 
out at room temperature. Cell nuclei were stained with 
4′,6-diamidino-2-phenylindole (DAPI) and cells were vis-
ualized under the Confocal Zeiss LSM 510 fluorescence 
microscope.
For Western blot analysis, infected DF-1 cells were 
lysed in radioimmunoprecipitation assay (RIPA) buffer 
and incubated on ice for 10 min then clarified by centrif-
ugation at maximum speed at 4 °C. The supernatant was 
mixed with SDS–PAGE sample buffer [125  mM Tris–
HCl (pH 6.8), 4.6% SDS, 50  mM DTT, 0.005% bromo-
phenol blue and 20% glycerol], denatured by heating in 
boiling water bath for 5 min, resolved by SDS–PAGE and 
analyzed by Western blot using chicken polyclonal anti-
IBV antibody.
To determine the incorporation of the S protein of 
IBV into the NDV particles, recombinant viruses were 
partially purified by ultracentrifugation. Briefly, 10  mL 
Table 1 Primers used for construction of the rNDV 
expressing IBV S protein vaccine candidates 
a The primer sequence is just upstream to the naturally present SmaI sequence 
at the nt position 2167 of the codon-optimized S gene sequence.
b The sequence “GGC” in bold indicates the reverse complementary mutagenic 
sequence of alanine residue at nt position 3433–3435 of the codon-optimized S 
gene sequence.
c The sequence “GCC” in bold indicates the mutagenic sequence of alanine 
residue at nt position 3433–3435 of the codon-optimized S gene sequence.
d Underlined sequence indicates StuI, italicized sequence in indicates PmeI, 
sequence in regular font indicates nt coding for optimized last 12 aa of NDV F 
protein, sequence in bold indicates the N terminus of IBV S specific sequence.
e Underlined sequence indicates StuI, italicized sequence indicates PmeI, 
sequence in regular font indicates nt coding for optimized last 12 aa of NDV 
F protein, sequence in bold indicates the N terminus of the transmembrane 
domain of IBV S specific sequence.
Primer 
number
Primer name Primer sequence
1 COS‑2167F (SmaI)a ACT CTG AAA GAC CTG ATC TGCG 
2 COS‑(YA) Rev AGT TGT GGC GTA GGA GCT TTT Cb
3 COS‑(YA) Fwd AGC TCC TAC GCC ACA ACT TTTG c
4 COS‑R (StuI‑PmeI‑Fct12) AGG CCT GTT TAA ACTCA CAT TTT 
AGT GGT TGC CCT CAT TTG ATC 
CAA AGT GTT CAC TGA TTT CTT 
GGG TCT GTAC d
5 COSΔct‑R (StuI‑PmeI‑Fct12) AGG CCT GTT TAA ACTCA CAT TTT 
AGT GGT TGC CCT CAT TTG ATC 
CAA AGT GTT AAA GAA GAT 
CCA CCC CAG GATC e
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of infective allantoic fluid of each recombinant virus 
was passed through 30% sucrose cushion for 2  h at 
28 000 rpm at 4 °C and the virus pellet was resuspended 
in 500  µL PBS. Partially purified LaSota virus was used 
as a negative control. The resuspended pellet was then 
mixed with SDS-PAGE sample buffer, heat denatured, 
resolved by SDS-PAGE, and analyzed by Western blot 
using chicken polyclonal anti-IBV antibody.
The pathogenicity of each recombinant NDV-vectored 
IBV vaccine candidate virus was compared to that of 
parental LaSota virus by the mean death time (MDT) 
assay in 10-day-old SPF ECE [45]. Briefly, 10-fold serial 
dilutions of the infective allantoic fluid were made in 
sterile PBS, and 100 µL of the dilutions ranging from  10−6 
to  10−9 were inoculated into four 10-day-old embryo-
nated eggs via allantoic sac route. Eggs were incubated at 
37 °C and examined three times daily for 7 days to record 
times of embryo mortality. The MDT was determined as 
mean time (h) for the minimum lethal dose of virus to kill 
all the inoculated embryos.
Evaluation of the protective efficacy of single‑dose 
vaccination against IBV and virulent NDV
To evaluate the protective efficacy against IBV, sixty 
1-day-old SPF White Leghorn chickens were divided 
into 5 groups and housed in negative pressure isolators 
with feed and water provided ad  libitum. Four groups 
containing 15, 10, 15 and 10 birds were vaccinated with 
 106 PFU/100  µL of rLaSota, rLaSota/wt.S, rLaSota/
S(Y1145A) + Fct12 and rLaSota/SΔct + Fct12, respectively, 
via oculonasal route. A fifth group, containing 10 birds, 
served as unvaccinated control.
Three weeks post-immunization, blood samples were 
collected from all birds to determine the level of hemag-
glutination inhibition (HI) antibody titers in the serum 
against NDV [46] and the antibody response against 
IBV using ELISA. After blood collection, 10 birds from 
all vaccinated groups and 5 birds from the unvaccinated 
control group were challenged with  104.2  EID50 of IBV/
Ck/EG/CU/4/2014 via oculonasal route. Birds were 
observed and scored for clinical signs until 10 days post-
challenge (dpc) before they were euthanized using  CO2 
euthanasia procedure approved by IACUC, University of 
Maryland. Scores include, 0 for normal, 1 for mild ocu-
lar discharge and mild nasal discharge and/or sneezing, 
2 for heavy ocular discharge and heavy nasal discharge 
and/or coughing, and 3 for tracheal rales and/or mouth 
breathing. At 5 dpc, tracheal and oropharyngeal swabs 
were collected from all birds to detect the level of viral 
shedding based on IBV-specific iTaq™ one-step universal 
probe RT-qPCR kit [47].
To evaluate the protective efficacy against NDV, 
5 birds from groups vaccinated with rLaSota and 
rLaSota/S(Y1145A) + Fct12 in addition to the unvacci-
nated control group were challenged with 100 chicken 
lethal dose 50%  (CLD50) of virulent NDV strain Texas GB, 
via oculonasal route, in the ABSL-3 + facility. The NDV 
strain Texas GB is used as a NDV challenge strain in the 
US. Birds were observed for clinical signs and mortality 
until 10 dpc. In IBV and NDV challenge studies, death/
mortality was not the endpoint, birds were scored for 
physical appearance, physical activity, neurological and/
or respiratory signs. When reached a cumulative score of 
6, birds were euthanized using  CO2 euthanasia procedure 
approved by IACUC, University of Maryland. Euthanized 
birds were scored as dead on the same day.
Evaluation of the protective efficacy of a prime‑boost 
vaccination strategy against IBV
Fifty 1-day-old SPF White Leghorn chicks were divided 
into 5 groups of 10 birds each and housed in nega-
tive pressure isolators with feed and water provided 
ad  libitum. Birds in groups 1, 2, 3 and 4 were immu-
nized (primed) with  106 PFU of rLaSota, rLaSota/wt.S, 
rLaSota/S(Y1145A) + Fct12 and rLaSota/SΔct + Fct12, 
respectively, at day 1 of age and boosted at day 14 of age 
via oculonasal route. Birds in group number 5 served as 
unvaccinated control. On day 35 of age (3  weeks post-
boost), birds in all groups were challenged with  105.2 of 
IBV/Ck/EG/CU/4/2014 via ocular route. Clinical signs 
were recorded daily for 10 dpc. At 5 dpc, tracheal and 
oropharyngeal swabs were collected from each bird to 
determine the level of viral shedding using IBV-specific 
iTaq one-step universal probe RT-qPCR kit [47]. Blood 
samples were collected at day 35 of age (just before chal-
lenge) to determine the serum HI antibody titers against 
NDV and antibody response against IBV using ELISA.
Determination of the antibody response against IBV
IBV-specific immune response was determined using 
ELISA. Briefly, ELISA plates (Nunc Maxisorp) were 
coated with heat-inactivated purified IBV/Ck/EG/
CU/4/2014 in carbonate-bicarbonate buffer, pH 9.8, at 
4 °C overnight. The IBV-coated plates were then blocked 
by 5% skim milk powder in PBS overnight at 4 °C. Plates 
were then loaded with serum samples diluted 1:100 in 
5% skim milk for 2  h at room temperature. Plates were 
washed, and IBV-specific antibodies were detected using 
the reagents in the commercial IBV ELISA kit (Synbiot-
ics, USA) according to the manufacturer instructions. 
Absorbance (optical density) was measured at 405  nm 
using BIOTEK ELx808 ELISA reader.
Statistical analysis
Statistical significance between different groups were 
determined using one-way analysis of variance (ANOVA) 
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followed by Tukey’s multiple comparison test using 
Prism 7 (GraphPad Software Inc., San Diego, CA) with P 
value < 0.05.
Results
Construction of rNDVs and analysis of IBV S protein 
expression
All the three forms of IBV S gene were inserted into the 
full-length cDNA clone of NDV strain LaSota between 
the P and M genes, and their corresponding recombi-
nant viruses, rLaSota/wt.S, rLaSota/S(Y1145A) + Fct12 
and rLaSota/SΔct + Fct12, were successfully rescued. The 
RT-PCR and DNA sequencing confirmed the presence of 
the three different forms of the IBV S gene in the rLaSota 
genomes. After the fifth passage in ECE, the presence 
of IBV S genes were detected by RT-PCR in the three 
recombinant viruses and confirmed by DNA sequenc-
ing, indicating that all recombinant viruses were geneti-
cally stable. The expression of S protein by rNDVs was 
detected by Western blot. Western blot analysis of the 
infected DF-1 cell lysates revealed three bands indicat-
ing S, S1 and S2 proteins of IBV. However, no bands were 
detected in mock and in rLaSota-infected DF-1 cells (Fig-
ure 2A, top panel). The expression of S protein by rNDVs 
was further confirmed by immunofluorescence. Immu-
nofluorescence analysis showed only intracellular expres-
sion of IBV S protein in DF-1 cells infected with rLaSota/
wt.S; whereas, both intracellular and surface expression 
of IBV S protein were observed in cells infected with 
rLaSota/S(Y1145A) + Fct12 and rLaSota/SΔct + Fct12. No 
expression of IBV S protein was detected in mock and 
rLaSota-infected cells (Figure 2B).
To determine whether the S protein expressed by 
rNDVs was incorporated into NDV virion, the rNDVs 
collected from infected eggs were partially purified 
through sucrose cushion. Western blot analysis of the 
partially purified recombinant viruses showed expres-
sion of the IBV S protein in rLaSota/S(Y1145A) + Fct12 
and rLaSota/SΔct + Fct12 but not in rLaSota/wt.S or in 
rLaSota. This indicates that fusion with the last 12 amino 
acids of NDV fusion protein resulted in the incorporation 
of IBV S protein into the NDV virion (Figure 2A, bottom 
panel).
In vitro characterization of IBV vaccine candidates
The multicycle growth kinetics of the rLaSota/wt.S, 
rLaSota/S(Y1145A) + Fct12 and rLaSota/SΔct + Fct12 
were evaluated in DF-1 cells in the presence of exogenous 
Figure 2 Expression of IBV S protein in DF‑1 cells infected with the rNDV‑vectored IBV vaccine candidates. A Western blot analysis of IBV S 
protein. DF‑1 cell lysates were analyzed 48 hpi by Western blot analysis using polyclonal IBV antisera (top panel). Analysis of incorporation of IBV S 
protein into purified rNDV virions from infective allantoic fluid by Western blot analysis using polyclonal IBV antisera (bottom panel). M, Marker; 1, 
rLaSota/wt.S; 2, rLaSota/S(Y1145A) + Fct12; 3, rLaSota/SΔct + Fct12; 4, rLaSota; 5, mock‑infected. B Immunofluorescence analysis of the intracellular 
and surface expression of IBV S protein in DF‑1 cells infected with the rNDV‑vectored IBV vaccine candidates. The cells were probed with polyclonal 
IBV antisera followed by detection with FITC‑conjugated goat anti‑chicken IgG antibodies (green) and DAPI (blue) and subsequently visualized 
using a confocal Zeiss LSM 510 fluorescence microscope.
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protease. The growth of all three recombinants were 
comparable with that of the parental rLaSota. The growth 
of rLaSota/wt.S, rLaSota/S(Y1145A) + Fct12 and rLa-
Sota/SΔct + Fct12 were slightly lower than parental rLa-
Sota till 48 hpi but by 60 hpi they reached titers similar 
to parental rLaSota. rLaSota, rLaSota/wt.S and rLaSota/
S(Y1145A) + Fct12 reached maximum titers of  106.6, 
 106.9 and  106.3  TCID50/mL, respectively, at 60 hpi, and 
rLaSota/SΔct + Fct12 reached a maximum titer of  106.6 
 TCID50/mL at 48 hpi (Figure 3).
The pathogenicity of each rNDV was evaluated in ECE 
by MDT assay. rLaSota/wt.S, rLaSota/S(Y1145A) + Fct12 
and rLaSota/SΔct + Fct12 showed MDT values of 134  h, 
137  h and 139  h, respectively, which were higher than 
that of the parental rLaSota (98  h) indicating that they 
are slightly attenuated than the parental rLaSota.
Protective efficacy of rNDVs expressing IBV S protein 
after single‑dose vaccination
To evaluate the protective efficacy of rNDVs express-
ing IBV S protein, 1-day-old SPF chicks were immu-
nized with single-dose of each virus and challenged after 
3 weeks with the Egyptian strain IBV/Ck/EG/CU/4/2014. 
Birds in all groups showed respiratory signs of varying 
severity, including lacrimation, nasal discharge, sneeze, 
cough, tracheal rales and mouth breathing, starting from 
3 dpc. Birds vaccinated with rLaSota/wt.S, rLaSota/
S(Y1145A) + Fct12 and rLaSota/SΔct + Fct12 showed 
significantly milder signs than birds in the control and 
rLaSota-vaccinated groups, especially at 4 and 5 dpc (Fig-
ure  4A). RT-qPCR results showed no significant reduc-
tion in tracheal shedding of IBV between the control and 
the vaccinated groups (Figure 4B).
Figure 3 Growth kinetics of rLaSota and rLaSota expressing 
different forms of IBV S protein of Egyptian IBV variant strain EG/
CU/4/2014. DF‑1 cells were infected with the indicated viruses at 
MOI of 0.01. Normal fresh chicken embryo allantoic fluid was added 
to the medium as exogenous source of protease. Samples of the 
supernatant media were collected at 12 h intervals and the viral titers 
were determined by limiting dilution on DF‑1 cells. Means and SEM of 
two independent experiments are plotted at each time point.
Figure 4 Protective efficacy of single‑dose vaccination of rNDV‑vectored IBV vaccine candidates in 1‑day‑old SPF chickens after IBV 
challenge. A Clinical signs in chickens immunized with the indicated vaccine candidates and challenged with  104.2  EID50 of Egyptian IBV variant 
strain EG/CU/4/2014. The birds were monitored daily for 10 days for clinical signs scoring (0 = normal, 1 = mild ocular discharge, mild nasal discharge 
and/or sneezing 2 = heavy ocular discharge, heavy nasal discharge and/or coughing 3 = tracheal rales and/or mouth breathing). Mean score and SEM 
are plotted for each group. Statistically significant differences versus the control group at each time point are indicated by asterisk. B Determination 
of viral load by RT‑qPCR quantitative analysis of IBV RNA in tracheal and oropharyngeal swabs collected at 5 days post IBV challenge. Each point 
indicates the viral load for an individual chicken, the lines indicate the mean viral load for each group, and the error bars indicate SEM.
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The IBV specific antibodies produced in vac-
cinated birds were assessed by ELISA. At 3  weeks 
post-immunization, chickens vaccinated with rLaSota/
S(Y1145A) + Fct12 and rLaSota/SΔct + Fct12 showed 
significant increase in ELISA antibody titers compared 
to the control non-vaccinated group (P < 0.001 and 
P < 0.01, respectively). However, the chickens vacci-
nated with rLaSota and rLaSota/wt.S did not show IBV 
specific ELISA antibody titers (Figure 5A).
The protective efficacy of rNDVs expressing IBV S 
protein was evaluated against virulent strain of NDV. 
Upon challenge with velogenic NDV strain Texas 
GB, all birds in groups vaccinated with rLaSota and 
rLaSota/S(Y1145A) + Fct12 did not show any clini-
cal signs or mortality, whereas all birds in the control 
group showed severe nervous signs and were eutha-
nized at 4 dpc. These results suggest that the rNDV 
vectored IBV vaccines provided protection also against 
NDV.
The antibody titers of vaccinated birds were evalu-
ated by the HI test. Three weeks post-immunization 
(prior to challenge), the means of serum HI anti-
body titers against NDV in groups vaccinated with 
rLaSota/wt.S, rLaSota/S(Y1145A) + Fct12 and rLa-
Sota/SΔct + Fct12 reached  log2 values of 3.2 ± 0.29, 
3.0 ± 0.19 and 3.4 + 0.22 which were significantly lower 
than that in the rLaSota-vaccinated group (5.1 ± 0.23) 
(Figure 5B).
Protective efficacy of rNDVs expressing S protein 
after prime‑boost vaccination
The 1-day-old SPF chicks were further evaluated for pro-
tective efficacy against challenge with the Egyptian strain 
IBV/Ck/EG/CU/4/2014 after prime-boost immunization 
with rNDVs expressing IBV S protein. After challenge 
with IBV/Ck/EG/CU/4/2014, birds in groups vaccinated 
with rLaSota/wt.S, rLaSota/S(Y1145A) + Fct12 and rLa-
Sota/SΔct + Fct12 showed significantly lower clinical 
signs scores than birds in control and rLaSota-vaccinated 
groups at 6 and 7 dpc (P < 0.01) (Figure  6A). RT-qPCR 
results revealed significant reduction of IBV shedding in 
birds vaccinated with rLaSota/wt.S (P < 0.05) compared 
to the control group. Whereas, birds vaccinated with 
rLaSota/S(Y1145A) + Fct12 and rLaSota/SΔct + Fct12 
showed very little, but not significant reduction of IBV 
shedding compared to the control group (Figure 6B).
The IBV specific antibodies elicited in the vaccinated 
birds after prime-boost vaccination were assessed by 
ELISA. Three weeks after boost, chickens vaccinated with 
rLaSota/S(Y1145A) + Fct12 and rLaSota/SΔct + Fct12 
showed significantly higher ELISA antibody titers com-
pared to the control non-vaccinated group (P < 0.01). 
However, the chickens vaccinated with rLaSota and 
rLaSota/wt.S did not show IBV specific ELISA antibody 
titers (Figure 7A).
The antibody titers against NDV in the vaccinated 
birds were evaluated by HI test. Two weeks after the 
first vaccination (before boost), the mean serum HI 
Figure 5 Antibody responses against IBV (A) and NDV (B) in 1‑day‑old SPF chicks vaccinated with different rNDV‑vectored IBV vaccine 
candidates. A The level of IBV‑specific antibodies in chicken serum samples on week 3 (prior to challenge) was determined by ELISA. Mean 
absorbance values and SEM are shown for each group. Statistically significant differences versus the control group are indicated by asterisk. B The 
level of NDV‑specific antibody titers in chicken serum samples on week 3 (prior to challenge) was determined by hemagglutination inhibition (HI) 
assay. Mean and SEM of each group are shown.
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titers against NDV induced by the three recombinant 
NDVs expressing the different forms of IBV S gene 
reached 2.4–3  log2 ± 0.31–0.42 which were signifi-
cantly lower than that induced by the parental rLaSota 
(4.9  log2 ± 0.43). Three weeks after boosting (before 
challenge), the mean serum HI titers in these groups 
increased to 5.7–6  log2 ± 0.26–0.32 which were com-
parable to that of rLaSota (6.2  log2 ± 0.35) (Figure 7B).
Figure 6 Protective efficacy of prime‑boost vaccination using rNDV‑vectored IBV vaccine candidates in 1‑day‑old SPF chickens against 
IBV challenge. A Clinical signs in chickens immunized at day 1 and day 14 of age with the indicated vaccine candidates and challenged at day 
35 of age with  105.2  EID50 per bird of Egyptian IBV variant strain EG/CU/4/2014. The birds were monitored daily for 10 days for clinical signs scoring 
(0 = no signs, 1 = mild ocular discharge, mild nasal discharge and/or sneezing 2 = heavy ocular discharge, heavy nasal discharge and/or coughing 
3 = tracheal rales and/or mouth breathing). Mean score and SEM are plotted for each group. Statistically significant differences versus the control 
group at each time point are indicated by asterisk. B Determination of viral load (of IBV challenge virus) quantitative analysis of IBV RNA in tracheal 
and oropharyngeal swabs collected at 5 days post IBV challenge by RT‑qPCR. Each point indicates the viral load for an individual chicken, the lines 
indicate the mean viral load for each group, and the error bars indicate SEM. Statistically significant differences are indicated by asterisk.
Figure 7 Antibody response against IBV (A) and NDV (B) in 1‑day‑old SPF chicks vaccinated at day 1 and day 14 of age with different 
rNDV vectored IBV vaccine candidates. A The level of IBV‑specific antibodies in chicken serum samples on week 5 (prior to challenge) was 
determined by ELISA. Mean absorbance values and SEM are shown for each group. Statistically significant differences versus the control group 
are indicated by asterisk. B The level of NDV‑specific antibody titers in chicken serum samples on week 2 (prior to boost) and on week 5 (prior to 
challenge) were determined by hemagglutination inhibition (HI) assay. Mean and SEM of each group are shown.
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Discussion
IB is a major disease problem in the poultry industry in 
Egypt [17]. Currently, classic and variant live-attenuated 
IBV vaccines are widely used in Egypt to control IB. 
These vaccines have been highly successful in controlling 
classical IBV strains in Egypt. However, these vaccines 
do not provide good protection against the circulating 
variant strains belonging to GI-23 lineage of IBV, which 
is prevalent in Egypt [17, 19]. A live-attenuated vaccine 
belonging to GI-23 lineage may provide better protection 
against prevalent field strains, but development of a new 
live-attenuated vaccine is expensive and time consum-
ing. Furthermore, a live-attenuated vaccine may revert to 
virulence, contributing to creation of new variant viruses 
[27]. Therefore, we have developed a vector vaccine 
against a prevalent Egyptian IBV variant strain. Develop-
ment of a vector vaccine is rapid, and it will not lead to 
creation of new IBV variants.
In this study, three NDV-vectored vaccine candidates 
were generated using three different forms of the S pro-
tein of Egyptian IBV strain EG/CU/4/2014: rLaSota/wt.S, 
rLaSota/S(Y1145A) + Fct12 and rLaSota/SΔct + Fct12. The 
IBV S protein in rLaSota/S(Y1145A) + Fct12 and rLaSota/
SΔct + Fct12 were modified to abolish the intracellular 
retention signal and to facilitate the transport of the IBV 
S protein to the cell surface [11]. This was done hypothe-
sizing that presenting the IBV S protein at the cell surface 
would elicit a better humoral immune response. In addi-
tion, the modified S proteins were fused with the last 12 
amino acids of NDV F protein to facilitate incorporation 
into the NDV virion envelope [48].
The whole S protein was used as the vaccine antigen 
instead of S1 or S2 protein because the S protein is highly 
conformation dependent. Some of the critical neutraliz-
ing epitopes on the S protein are formed by amino acids 
from both S1 and S2 proteins and these epitopes will be 
lost if they are separated. This was recently confirmed by 
Shirvani et al. [40]. In the present study, we have evalu-
ated two additional forms of S protein which were not 
evaluated by Shirvani et al. [40].
In this study, NDV was chosen as the vaccine vector 
for IBV considering that the vaccine can protect against 
both IB and ND [40], which are enzootic in Egypt. All 
three NDV-vectored IBV vaccine candidates expressed 
S protein of IBV at high levels after five passages in ECE 
indicating that the S gene insertion was genetically stable. 
Our results showed that all three vaccine candidates grew 
to high titers in ECE  (28 HAU) which makes them suit-
able for mass vaccine production. All the vaccine candi-
dates were slightly attenuated compared to the parental 
rLaSota virus by MDT assay.
One-day-old chickens immunized by all three rNDVs 
expressing the IBV S protein showed clinical protection 
against challenge with the Egyptian IBV strain EG/
CU/4/2014. Although the three IBV vaccine candidates 
significantly reduced the severity of the clinical signs, 
they did not show reduction in tracheal viral shedding, 
which is another important criterion for determining the 
efficacy of an IBV vaccine. This result indicates that the 
immune responses elicited by single immunization may 
not be high enough to stop the virus shedding from the 
respiratory tract. It should be noted that IBV is a highly 
infectious and a fast replicating virus [49]. Therefore, it 
will require a high level of high affinity neutralizing anti-
bodies and cell mediated immune response to completely 
block IBV replication in the respiratory tract, which 
is not achievable by live-attenuated IBV vaccine. Our 
results are in agreement with previous reports that rNDV 
expressing S protein prevent disease but do not stop virus 
shedding [40]. Another possible explanation is that the 
1-day-old chicks may have immature immune system 
that could not have elicited a robust protective immune 
response after single immunization. It has been shown 
that vaccination of SPF chicks by IBV vaccines at day 1 
of age, and to a lesser extent at day 7 of age, provided a 
poorly protective IBV specific immune responses, while 
vaccination at day 14 of age and older provided better 
protection against IBV challenge [50].
In the prime-boost immunization study, rLaSota/wt.S 
provided significant protection in terms of alleviation 
of clinical signs and reduction of tracheal viral shedding 
after IBV challenge. However, rLaSota/S(Y1145A) + Fct12 
and rLaSota/SΔct + Fct12 provided only protection 
against the clinical disease but did not significantly 
decrease the tracheal viral shedding. This could be 
because the IBV S protein in case of rLaSota/wt.S elicited 
more effective cell mediated immune response, which 
is crucial for clearance of the IBV from the respiratory 
tract [1, 51–54] and also it has been reported that the 
humoral antibody titer does not correlate with the resist-
ance to respiratory infection [1, 55, 56]. Another possible 
explanation is that the modifications done in the S pro-
tein of IBV in rLaSota/S(Y1145A) + Fct12 and in LaSota/
SΔct + Fct12 could have changed the conformation of 
the IBV S protein and/or rendered loss of critical T cell 
epitopes necessary for effective blocking of IBV infection. 
Our results suggest that wild type S protein of IBV is the 
best protective antigen. Any modification to the S protein 
can affect the protective efficacy of the protein.
Notably, the rLaSota/wt.S provided significant pro-
tection against IBV challenge in the prime-boost vacci-
nation experiment even though the challenge dose was 
increased to  105.2  EID50 per bird. This indicates that the 
prime-boost vaccination strategy can provide a protec-
tive immune response against a high dose IBV challenge. 
There is also a need to investigate further if single-dose 
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vaccination of chickens at older age (2-week and older) 
may be enough to provide a protective immune response 
against IBV challenge due to the well-developed immune 
system at this age [50].
The ELISA results showed that rLaSota/wt.S did 
not produce significant increase in the IBV-specific 
serum antibody titers. On the other hand, the rLaSota/
S(Y1145A) + Fct12 and rLaSota/SΔct + Fct12 showed a 
significant increase in the IBV-specific antibody titers. 
A possible explanation is that the surface expression of 
the IBV S protein and its incorporation into the NDV 
virion, in case of rLaSota/S(Y1145A) + Fct12 and rLaSota/
SΔct + Fct12 elicited much stronger humoral immune 
response compared to the rLaSota/wt.S which showed 
only intracellular expression of the S protein. Moreo-
ver, coating the ELISA plates with an inactivated whole 
IBV could have also increased the detection threshold of 
the IBV-specific humoral antibodies which were raised 
against S protein alone. Similarly, Eldemery and cowork-
ers reported a higher level of antibodies against IBV S 
protein when S-ectodomain-coated-ELISA plates were 
used compared to whole-virus-coated-plates [57].
In summary, recombinant NDV strain LaSota express-
ing three different forms of the chicken-codon-optimized 
S protein of a prevalent Egyptian IBV variant strain were 
generated and evaluated for use as bivalent vaccines in 
Egypt. This study confirmed and extended the work of 
Shirvani et al. [40] that the whole S protein is the antigen 
of choice for generating an efficient vectored IBV vaccine. 
Our results showed that any modification to the S pro-
tein can affect its protective efficacy. Our results further 
showed that recombinant NDV expressing the wild type 
S protein of an Egyptian variant strain (rLaSota/wt.S) 
provided protection from clinical disease against a preva-
lent Egyptian variant strain of IBV and reduced virus 
shedding (prime-boost immunization), indicating that 
this vaccine candidate has the potential for controlling 
IBV in Egypt. Furthermore, NDV-vectored IBV vaccine 
will protect both IBV and NDV. This vaccine will also 
benefit countries neighboring to Egypt, where antigeni-
cally similar IBV strains are prevalent. Thus, suggesting 
that similar NDV-vectored vaccines can be engineered 
for use against circulating IBV strains in other geographi-
cal regions.
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Additional file 1. Cloning of three different forms of IBV S protein 
into pUC57. (A) Chicken‑codon‑optimized wild type IBV S gene cloned 
into pUC57 (pUC57‑CO.S). IBV S protein domains: ectodomain, transmem‑
brane (TM) and cytoplasmic tail are represented in blue boxes, preceded 
by NDV gene‑end (GE, in Red), intergenic (IGS, in black), gene‑start (GS, in 
green) and Kozak (in white) sequences, and flanked by PmeI sites. Dotted 
numbers indicate amino acid positions in the cytoplasmic tail of IBV S 
protein. Arrows with circled numbers indicate the primers used to induce 
the S protein modifications using pUC57‑CO.S as template (refer Table 1 
for the primers). (B) Primers 1, 2, 3 and 4 used to induce the “Y1145A” 
mutation and add the last 12 aa of the cytoplasmic tail of NDV F protein 
 (Fct12, represented in grey box) to create pUC57‑CO.S(Y1145A)+Fct12 (C) 
Primers 1 and 5 used to replace the cytoplasmic tail of IBV S protein by 
the last 12 aa of the cytoplasmic tail of NDV F protein to create pUC57‑CO.
SΔct+Fct12.
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